B-cell epitopes in HIV-1 TAT and rev proteins colocalize with T-cell epitopes and with functional domains

Biomedicine and Pharmacotherapy

Volumn 51, Issue 10, 1997, Pages 480-487

  Tahtinen M ^a   Ranki, A ^b   Valle, S L ^c   Ovod, V ^d   Krohn, K ^a  

^a UNIVERSITY OF TAMPERE   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d NONE

Author keywords

B cell epitopes; Epitope mapping; Rev; Synthetic peptides; Tat

Indexed keywords

EPITOPE; REV PROTEIN; TRANSACTIVATOR PROTEIN;

ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; T LYMPHOCYTE;

EID: 0345404337     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(97)82330-X     Document Type: Article

References (35)

1. Rosen CA, Pavlakis GN. Tat and Rev : positive regulators of HIV gene expression. AIDS 1990;4:499-509
2. Aldovini A, Debouck C, Feinberg MB, Rosenberg M, Arya SK, Wong-Staal F. Synthesis of the complete trans-activation gene product of human T-lymphotropic virus type III in Eschericia coli : Demonstration of immunogenicity in vivo and expression in vitro. Proc Natl Acad Sci USA 1986;83:6672-6
3. Barone AD, Silva JA, Ho DD, Gallo RC, Wong-Staal F, Chang NT. Reactivity of E coli derived trans-activating protein of human lymphotropic virus type III with sera from patients with acquired immune deficiency syndrome. J Immunol 1986;137:669-73
4. Chanda PK, Ghrayeb J, Wong-Staal F. Non-random distribution of antibodies to the TRS protein of human immunodeficiency virus in infected people with different clinical status. AIDS Res Hum Retroviruses 1988;4:11-16
5. Dairaku M, Tsuchie H, Ushijima H, Aoki I, Okuda K, Hon-da M et al. Incidence and titer of anti-Rev antibody in HIV infection. AIDS 1989;3:765-6
6. Franchini G, Robert-Guroff M, Aldovini A, Kan NC, Wong-Staal F. Spectrum of antibodies against five HTLV-III antigens in infected individuals : Correlation of antibody prevalence with clinical status. Blood 1987;69:437-41
7. Krone WJA, Debouck C, Epstein L, Heutink P, Meloen R, Goudsmit J. Natural antibodies to HIV-Tat epitopes and expression of HIV-1 genes in vivo. J Med Virol 1988;26:261-70
8. Reiss P, de Ronde A, Dekker J, Aramideh M, de Wolf F, Debouck C et al. Seroconversion to HIV-1 Rev-and Tat-gene encoded proteins. AIDS 1989;3:105-7
9. Reiss P, de Ronde A, Lange JMA, de Wolf F, Dekker J, Damner SA et al. Low antigenicity of HIV-1 Rev : Rev-specific antibody response of limited value as correlate of Rev gene expression and disease progression. AIDS Res Hum Retroviruses 1989;5:621-8
10. Brake DA, Goudsmit J, Krone WJA, Schammel P, Appleby N, Meloen RB et al. Characterization of murine monoclonal antibodies to the Tat protein from human immunodeficiency virus type 1. J Virol 1990;64:962-5
11. Kreusel J, Aepinus C, Lang S, Beninga J, Prenzel S, Fleckenstein B. Mouse monoclonal antibodies recognize the activation domain of HIV-1 Rev transactivator. Mol and Cell Probes 1993;7:111-19
12. Pardridge WM, Bickel U, Buciak J, Yang J, Diagne A. Enhanced endocytosis and anti-human immunodeficiency virus type I activity of anti-Rev antibodies after cationization. J Inf Dis 1994;169 :55-61
13. Devash Y, Reagan K, Wood D, Turner J, Parrington M, Kang CY. Antibodies against AIDS proteins. Nature 1990;345 :581
14. Reiss P, Lange JMA, de Ronde A, de Wolf F, Dekker J, Debouck C, Goudsmit J. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J Med Virol 1990;30:163-8
15. Re MC, Furlini G, Vignoli M, Ramazotti E, Roderigo G, De Rosa V et al. Effect of antibody to HIV-1 tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquir Immune Defic Sndr Hum Retrovirol 1995;10:408-16
16. Reiss P, de Wolf F, Kuiken CL, de Ronde A, Dekker J, Boucher CAB et al. Contribution of antibody response to recombinant HIV-1 gene-encoded products Nef, Rev, Tat, and protease in predicting development of AIDS in HIV-1-infected individuals. J Acquit Immune Deficit Syndr 1991;4:165-72
17. Steinaa L, Soresen QM, Nielsen Jo, Hansen JES et al. Antibody to HIV-1 Tat protein inhibits the replication of virus in culture. Arch Virol 1994;139:263-71
18. Ramazzotti E, Vignoli M, Re MC, Furlini G, La Placa M. Enhanced nuclear factor-KB activation induced by tumour necrosis factor-α in stably Tat-transfected cells is associated with the presence of cell-surface-bound Tat protein. AIDS 1996;10:455-61
19. Ranki A, Lagerstedt A, Ovod V, Aavik E, Krohn KJE. Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lymphoid cell lines. Arch Virol 1994;139:365-78
20. McPhee D et al. Recognition of envelope and Tat protein synthetic peptide analogs by HIV positive sera or plasma. FEBS Lett 1988;233:393-6
21. Blazevic V, Ranki A, Mattinen S, Valle S-L, Koskimies S, Jung G, Krohn KJE. Helper T-cell recognition of HIV-1 Tat synthetic peptides. J Aqui Immune Defic Syndr 1993;6:881-90
22. Blazevic V Ranki A, Krohn KJE. Helper and cytotoxic T-cell responses of HIV type 1-infected individuals to synthetic peptides of HIV type 1 Rev. AIDS Res Hum Retroviruses 1995;11:1335-41
23. Gombert FO, Blecha W, Tähtinen M, Ranki A, Pfeifer S, Tröger W et al. Antigenic epitopes of NEF proteins from different HIV-1 strains as recognized by sera from patients with manifest and latent HIV infection. Virology 199D;176:458-66
24. Geysen M, Rodda JS, Mason JT, Tribbick G, Shoofs PG. Strategies for epitope analysis using peptide synthesis. J Immunol Methods 1987;102:259-74
25. Myers G, Rabson AB, Berzofsky JA, Smith TF, Wong-Staal F, eds. Human Retroviruses and AIDS. Los Alamos : Los Alamos National Laboratory. 1990
26. Frankel AD, Bredt DS, Pabo CO. Tat protein from human immunodeficiency virus forms a metal-linked dimer. Science 1988;40:70-3
27. Koken S, Greijer AE, Verhoef K, van Wamel J, Berkhout B. Intracellular analysis of in vitro modified HIV Tat protein. J Biol Chem 1994;269:8366-75
28. Dingwell C, Ernberg I, Gait MJ, Green SM, Heaphy S, Karn J. Human immunodeficiency virus 1 Tat protein binds transactivation response region (TAR) RNA in vitro. Proc Natl Acad Sci USA 1989;86:6925-9
29. Ruben S, Perkins A, Purcell K, Joung K, Sia R, Burghoff R. Structural and functional characterization of human immunodeficiency virus Tat protein. J Virol 1989;63:1-8
30. Kolson DL, Buchhalter J, Collman R, Hellmig B, Farrel CF, Debouck C et al. HIV-1 Tat alter normal organization of neurons and astrocytes in primary rodent brain cell cultures : RGD sequence dependence. AIDS Res Hum Retroviruses 1993;9:677-85
31. Berger J, Aepinus C, Dobrovnik M, Fleckenstein B, Hauber J, Boehnlein E. Mutational analysis of functional domains in the HIV-1 Rev trans-regulatory protein. Virology 1991;183:630-5
32. Cochrane A, Perkins A, Rosen C. Identification of sequences important in the nucleolar localization of human immunodeficiency virus Rev : relevance of nucleolar localization to function. J Virol 1990;64:881-5
33. Kjems J, Calnan BJ, Frankel AD, Sharp PA. Specific binding of a basic peptide from HIV-1 Rev. EMBO J 1992;11:1119-29
34. Malim MH, Bohnlein S, Hauber J, Cullen BR. Functional dissection of the HIV-1 Rev trans-activator-derivation of a trans-dominant represser of Rev function. Cell 1989;58:205-14
35. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993;67:277-87